Search research articles
Contact Us
Filters
Showing results (141-150 of 154) with videos related to
Page
of 16
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
August 18, 2000
Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells
H R Salih, S G Kosowski, V F Haluska, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 29, 2002
Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages
Gene M Dubowchik, Shilpa Radia, Harold Mastalerz, et al.
Cancer Immunology Research
|
March 23, 2022
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
Nicolò Rigamonti, Niina Veitonmäki, Clara Domke, et al.
The Bone & Joint Journal
|
December 3, 2016
Medium-term outcomes of the Universal-2 total wrist arthroplasty in patients with rheumatoid arthritis
R Badge, K Kailash, D R Dickson, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
December 5, 1998
Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis
W R Ji, F J Castellino, Y Chang, et al.
Cancer Research
|
December 4, 2001
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291
J G Naglich, M Jure-Kunkel, E Gupta, et al.
Cancer Research
|
January 20, 2011
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth
Jin Gao, Jon W Chesebrough, Susan A Cartlidge, et al.
Cancer Chemotherapy and Pharmacology
|
December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S Chang, Jalila Adnane, Pamela A Trail, et al.
Leukemia
|
January 6, 2007
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D Auclair, D Miller, V Yatsula, et al.
Molecular Cancer Therapeutics
|
April 6, 2017
Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Marcus P Kelly, Carlos Hickey, Sosina Makonnen, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 154) with videos related to
Sort By:
Page
of 16
Journal of Immunology (Baltimore, Md. : 1950)
|
August 18, 2000
Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells
H R Salih, S G Kosowski, V F Haluska, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 29, 2002
Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages
Gene M Dubowchik, Shilpa Radia, Harold Mastalerz, et al.
Cancer Immunology Research
|
March 23, 2022
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
Nicolò Rigamonti, Niina Veitonmäki, Clara Domke, et al.
The Bone & Joint Journal
|
December 3, 2016
Medium-term outcomes of the Universal-2 total wrist arthroplasty in patients with rheumatoid arthritis
R Badge, K Kailash, D R Dickson, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
December 5, 1998
Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis
W R Ji, F J Castellino, Y Chang, et al.
Cancer Research
|
December 4, 2001
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291
J G Naglich, M Jure-Kunkel, E Gupta, et al.
Cancer Research
|
January 20, 2011
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth
Jin Gao, Jon W Chesebrough, Susan A Cartlidge, et al.
Cancer Chemotherapy and Pharmacology
|
December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S Chang, Jalila Adnane, Pamela A Trail, et al.
Leukemia
|
January 6, 2007
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D Auclair, D Miller, V Yatsula, et al.
Molecular Cancer Therapeutics
|
April 6, 2017
Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Marcus P Kelly, Carlos Hickey, Sosina Makonnen, et al.
Page
of 16